T-cell Leukemia Clinical Trials

4 recruiting

Frequently Asked Questions

Common questions about T-cell Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 2

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

LymphomaT-cell LeukemiaT-Cell Leukemia/Lymphoma, Adult+1 more
Memorial Sloan Kettering Cancer Center134 enrolled7 locationsNCT06698003
Recruiting
Phase 1

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Recurrent Adult T-Cell Leukemia/LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Adult T-Cell Leukemia/Lymphoma+1 more
John Reneau12 enrolled1 locationNCT04848064
Recruiting
Phase 2

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

T-cell LymphomaT-cell Prolymphocytic LeukemiaLymphoma, T-Cell+5 more
Jonathan Brammer44 enrolled1 locationNCT07356245
Recruiting
Phase 1

CD4CAR for CD4+ Leukemia and Lymphoma

T-cell LymphomaT-cell Leukemia
Huda Salman20 enrolled6 locationsNCT03829540
Recruiting

Novel Therapeutic Approach for Human T-cell Malignancies

T-Cell Leukemia/Lymphoma, Adult
Istituto Oncologico Veneto IRCCS120 enrolled2 locationsNCT06600568
Recruiting

Observatory of Prolymphocytic Leukemia T

Prolymphocytic LeukemiaT-cell Leukemia
French Innovative Leukemia Organisation50 enrolled1 locationNCT04411043
Recruiting
Phase 2

Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation

Acute Myeloid LeukemiaMixed Phenotype Acute LeukemiaAcute Lymphoblastic T-cell Leukemia
Federal Research Institute of Pediatric Hematology, Oncology and Immunology15 enrolled1 locationNCT07256210
Recruiting
Phase 1Phase 2

A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma

Adult T-Cell Leukemia/Lymphoma (ATLL)
Otsuka Medical Devices Co., Ltd. Japan49 enrolled4 locationsNCT07075328
Recruiting
Phase 2

Two Step Haplo With Radiation Conditioning

Hematopoietic and Lymphatic System NeoplasmAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+14 more
Thomas Jefferson University63 enrolled1 locationNCT05031897
Recruiting
Phase 2

Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients

Adult T-cell Leukemia/Lymphoma
The First Affiliated Hospital of Soochow University27 enrolled1 locationNCT07159620
Recruiting

A Registry for People With T-cell Lymphoma

T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic Leukemia+27 more
Memorial Sloan Kettering Cancer Center1,000 enrolled26 locationsNCT05978141
Recruiting
Phase 1Phase 2

Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells

T-cell LymphomaT-cell Prolymphocytic LeukemiaT-cell Acute Lymphoblastic Leukemia+3 more
Essen Biotech60 enrolled1 locationNCT06420076